MH3D, Inc. Announces Purchase of Alpha-SPECT Mini Unit by Minerva Imaging

Ann Arbor, MI —April 20^th, 2026— MH3D, Inc., a leader in next-generation quantitative SPECT imaging technology, today announced that Minerva Imaging, a globally recognized contract research organization (CRO), has purchased an Alpha-SPECT^TM Mini unit, marking the first adoption of MH3D’s technology in Europe.

This commercial milestone represents growing demand for high-precision, quantitative imaging solutions in pre-clinical theranostics research. 

MH3D’s Alpha-SPECT^TM Mini is designed to address a critical gap in the field: the lack of accurate, quantitative imaging solutions for alpha- and beta-emitting radiopharmaceuticals. Leveraging CZT-based detector technology, advanced energy discrimination, and high-sensitivity collimation design, the system enables multi-isotope imaging and supports absolute quantification with high fidelity.

Minerva Imaging’s purchase reflects increasing industry demand for imaging platforms capable of delivering transparent, quantitative data for radiopharmaceutical development and evaluation.

The system will be used to support applications including biodistribution studies, dosimetry analysis, and longitudinal imaging of theranostic agents.

“We are pleased to see the Alpha-SPECT^TM Mini adopted by Minerva Imaging, an organization with deep expertise in radiopharmaceutical imaging,” said Xiaopei Huang, CEO and Founder of MH3D. “Their focus on alpha emitters and actinium-based therapies aligns perfectly with the system’s design principles of accuracy, sensitivity, and robust isotope characterization. As this is the first system in Europe, we look forward to supporting Minerva Imaging in serving their partners and advancing the field of preclinical imaging across Europe.”

“With the increasing clinical and commercial focus on actinium based and other alpha emitting therapies, there is a clear need for highly accurate and sensitive imaging solutions,” said Carsten H. Nielsen at Minerva Imaging. “The Alpha-SPECT^TM Mini system significantly enhances our ability to support our clients in this space, particularly where in vivo biodistribution data and assessment of daughter isotopes are critical. We are beyond excited to acquire the first preclinical system truly optimized for alpha-emitter theranostics.”

This announcement underscores a broader shift toward quantitative and reproducible imaging in preclinical research, particularly as radiopharmaceutical pipelines continue to expand.

About MH3D, Inc.

MH3D, Inc. is a medical imaging company developing next generation quantitative SPECT systems, powered by CZT detectors and advanced nuclear medicine imaging software. The company focuses on the Alpha-SPECT^TM platform enabling absolute quantification for theranostics across pre-clinical and future clinical applications.

Learn more about MH3D, Inc. at https://www.mh3dinc.com/.

About Minerva Imaging

Minerva Imaging is a specialized imaging CRO providing advanced preclinical imaging services to support radiopharmaceutical and drug development. With deep expertise in nuclear imaging and translational research, Minerva Imaging partners with pharmaceutical and biotechnology companies globally to accelerate innovation in molecular imaging and targeted therapies.